

In the claims

Please replace originally filed claims with the claims indicated below:

Patent Claims

1. (original)  $\delta$  crystalline form of perindopril erbumine, characterised by the following X-ray diffraction data (measured on a powder diffractometer with  $\text{CuK}\alpha$  irradiation):

Angle 2 theta (°)	Lattice spacing  $d$ (Å)	Relative intensity  $I/I_{\text{max}}$ (%)
5.27	16.79	2
8.93	9.93	100
9.75	9.10	32
10.65	8.34	10
14.63	6.10	25
14.97	5.97	39
15.27	5.85	48
15.95	5.61	53
17.27	5.19	18
17.87	5.02	15

18.63	4.83	13
19.99	4.51	29
20.37	4.43	26
21.31	4.24	57
21.83	4.15	37
22.49	4.03	26
23.15	3.92	19
23.65	3.84	29
23.99	3.79	16
24.71	3.69	15
25.33	3.60	15
25.75	3.55	15
26.43	3.46	21
26.77	3.42	18
28.19	3.26	24

2. (cancelled)

3. (previously presented) Crystalline forms of perindopril erbumine according to claim 1 for use as therapeutic active substances.

4. (previously presented) Medicaments, containing a crystalline form of perindopril erbumine according to claim 1.

5. (currently amended) A phamaceutical composition comprising as active ingredient the compound ~~methed for the treatment of cardiovascular diseases comprising the steps of:~~  
~~————— providing a crystalline forms of perindopril erbumine according to claim 1, +~~  
~~————— processing said crystalline forms of perindopril erbumine together with a~~ in combination with one or more ~~pharmaceutically acceptable, inert, non-toxic carriers material to form a medicament; and~~  
~~————— administering said medicament to an individual suffering from a cardiovascular disease.~~

6. (currently amended) A The phamaceutical composition according to claim 5 ~~methed for use in the treatment of cardiovascular diseases, according to claim 5, where said cardiovascular diseases are high blood pressure and heart failure.~~

7. (original) Process for the preparation of perindopril erbumine of the  $\delta$  crystalline form according to claim 1, characterised in that

a) perindopril erbumine of any crystalline form is recrystallised at from 30 to 45°C from tert-butyl methyl ether containing from 1.5 to 2.5 % (v/v) water, and the precipitate obtained is stirred for at least 15 hours at from 30 to 45°C after the removal of water;

or

b) perindopril erbumine of the  $\alpha$  or  $\beta$  crystalline form is stirred at from 33 to 38°C in tert.-butyl methyl ether containing from 0.9 to 1.4 % (v/v) water with seeding with the  $\delta$  crystalline form.

8. (cancelled)

9. (cancelled)

10. (cancelled)

11. (previously presented) A method for the preparation of medicaments comprising the steps of:

providing a crystalline forms of perindopril erbumine according to claim 1;

processing said crystalline forms of perindopril erbumine together with a pharmaceutically acceptable carrier material to form a medicament.

12. (cancelled)

13. (cancelled)

14. (new) The pharmaceutical composition according to claim 6 where said cardiovascular diseases are high blood pressure and heart failure.